Is It Time To Reconsider BioNTech (BNTX) After Its Recent Share Price Weakness?

• If you are wondering whether BioNTech's current share price lines up with its long term potential, starting with a clear look at valuation can help you frame that question more calmly.
• BioNTech's shares recently closed at US$90.10, with returns of 11.6% decline over the past week, 17.3% decline over the last month, and 6.8% decline year to date, alongside 7.6% decline over 1 year, 31.7% decline over 3 years, and 12.2% decline over 5 years, which hints that the market's view on risk and opportunity has been shifting.
• Recent news around BioNTech has focused on its position in pharmaceuticals and biotech and how investors weigh its long term pipeline potential against changing expectations for its existing products. This context helps explain why the share price has been moving even without a single headline acting as the sole driver.
• On Simply Wall St's valuation checks, BioNTech scores 3 out of 6, as shown by its valuation score of 3. Next, we will look at what different valuation approaches say about that number and then consider an even richer way to think about what the stock might be worth.

Find out why BioNTech's -7.6% return over the last year is lagging behind its peers.

Approach 1: BioNTech Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today to arrive at an estimate of what the whole business might be worth right now.

For BioNTech, the model used is a 2 stage Free Cash Flow to Equity approach, based on cash flow projections in €. The latest twelve month free cash flow is a loss of about €123.7 million. Analyst inputs and Simply Wall St extrapolations imply that free cash flow could still be negative in several coming years, then turn positive, with a projected €438.96 million in 2030 and higher figures in later years, all expressed in millions rather than billions.

After discounting these projected cash flows back to today, the model arrives at an estimated intrinsic value of €165.22 per share. Compared to a recent share price of US$90.10, this implies roughly a 45.5% discount, which indicates that BioNTech is trading below this particular estimate of fair value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BioNTech is undervalued by 45.5%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for BioNTech.

Approach 2: BioNTech Price vs Sales

For companies where earnings can be uneven, the P/S ratio is often a useful cross check because it links the share price to the revenue the business is already generating, rather than to current profits alone.

What counts as a reasonable P/S depends on what investors expect for future growth and how risky they feel the company is. Higher expected growth or lower perceived risk can justify a higher multiple, while lower growth or higher uncertainty tends to pull the multiple down.

BioNTech is trading on a P/S of 6.54x. That compares with an average of 12.25x for the broader Biotechs industry and about 5.81x across its peers. Simply Wall St also calculates a Fair Ratio of 5.73x, which is the P/S level it would expect for BioNTech after weighing factors such as earnings growth estimates, profit margins, its industry, market cap and specific risks.

This Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for BioNTech’s own profile instead of assuming one size fits all. With the actual P/S at 6.54x versus a Fair Ratio of 5.73x, the shares screen as overvalued on this measure.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your BioNTech Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce Narratives. With Narratives you set out your story for BioNTech, link that story to explicit assumptions for future revenue, earnings and margins, and end up with a fair value you can compare to the current share price.

On Simply Wall St’s Community page, Narratives give you a simple framework that ties the company’s story to a financial forecast and then to a fair value. This allows you to quickly see whether your view suggests BioNTech is worth more or less than today’s price and use that to help decide if it feels more like a potential buy, hold or sell in your own process.

These Narratives update automatically when new earnings, news or clinical data arrive. This means a more optimistic BioNTech view that targets, for example, a fair value around US$499.94 and a more cautious view closer to about US$99.66 can both coexist, reflecting different assumptions and giving you a clear sense of where your own expectations sit between the highest and lowest assessments on the platform.

Do you think there's more to the story for BioNTech? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com